Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
February 23, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders

CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
February 06, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Douglas...
January 16, 2018 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that the...
November 15, 2017 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Announces $18 Million Private Placement Offering

CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has...
November 13, 2017 07:00 ET | Source: Leap Therapeutics, Inc.

Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
September 19, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics to Present at the 2017 Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that...
September 08, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers

CAMBRIDGE, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an...
August 11, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics Reports Second Quarter 2017 Financial Results

CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial...
June 26, 2017 07:00 ET | Source: Leap Therapeutics

Leap Therapeutics Added to Russell Microcap® Index

CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that it was...